We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
The effects of vitamin D supplementation on endothelial activation among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials.
Background and objective: The current systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to summarize the effect of vitamin D supplementation on endothelial activation among patients with metabolic syndrome and related disorders.
Methods: Cochrane library, Embase, PubMed, and Web of Science database were searched to identify related RCTs published before 30th April 2018. The heterogeneity among the included studies was assessed using Cochran's Q test and I-square (I2 ) statistic. Data were pooled by using the random-effect model and standardized mean difference (SMD) was considered as summary effect size.
Results: Fourteen clinical trials that contained a total of 1253 participants were included in the current meta-analysis. Vitamin D supplementation significantly decreased von willebrand factor (vWF) (SMD -0.27; 95% CI, - 0.46, - 0.08; P = 0.006; I2 :40.5%). However, we found no significant impact of vitamin D supplementation on intercellular adhesion molecule 1(ICAM-1) (SMD -1.96; 95% CI, - 4.02, 0.09; P = 0.06; I2 :97.4%), vascular celladhesion molecule 1 (VCAM-1) (SMD -0.50; 95% CI, - 1.19, 0.19; P = 0.15; I2 :91.2%), on E-selectin (SMD -0.04; 95% CI, - 0.36, 0.28; P = 0.81; I2 :78.8%) and endothelin (SMD -0.49; 95% CI, - 1.18, 0.19; P = 0.15; I2 :90.5%). The pooled data from trials of vitamin D supplementation with dosage of ≤4000 IU/day (- 0.37, 95% CI: -0.65, - 0.10, I2 : 73.5%) significantly reduced vWF concentrations, while there was no effect of vitamin D supplementation on vWF concentrations among trials with the dosage of intervention > 4000 IU/day (- 0.17, 95% CI: -0.43, 0.10, I2 : 0.0%). VWF concentrations significantly reduced in pooled data from trials with duration study ≤8 weeks (- 0.37, 95% CI: -0.67, - 0.07, I2 : 60.6%), but there was no effect of vitamin D supplementation on vWF concentrations among trials with > 8 weeks (- 0.20, 95% CI: -0.45, 0.05, I2 : 0.0%). While there was no effect of vitamin D supplementation on vWF concentrations among trials with total sample size of ≤60 patients (- 0.03, 95% CI: -0.42, 0.36, I2 : 0.0%), vWF concentrations in trials with more than 60 patients decreased significantly (- 0.34, 95% CI: -0.56, - 0.12, I2 : 60.9%).
Conclusions: Overall, the current meta-analysis demonstrated that vitamin D supplementation to patients with metabolic syndrome and related disorders resulted in an improvement in vWF, but did not affect ICAM-1, VCAM-1, E-selectin and endothelin levels.
Methods: Cochrane library, Embase, PubMed, and Web of Science database were searched to identify related RCTs published before 30th April 2018. The heterogeneity among the included studies was assessed using Cochran's Q test and I-square (I2 ) statistic. Data were pooled by using the random-effect model and standardized mean difference (SMD) was considered as summary effect size.
Results: Fourteen clinical trials that contained a total of 1253 participants were included in the current meta-analysis. Vitamin D supplementation significantly decreased von willebrand factor (vWF) (SMD -0.27; 95% CI, - 0.46, - 0.08; P = 0.006; I2 :40.5%). However, we found no significant impact of vitamin D supplementation on intercellular adhesion molecule 1(ICAM-1) (SMD -1.96; 95% CI, - 4.02, 0.09; P = 0.06; I2 :97.4%), vascular celladhesion molecule 1 (VCAM-1) (SMD -0.50; 95% CI, - 1.19, 0.19; P = 0.15; I2 :91.2%), on E-selectin (SMD -0.04; 95% CI, - 0.36, 0.28; P = 0.81; I2 :78.8%) and endothelin (SMD -0.49; 95% CI, - 1.18, 0.19; P = 0.15; I2 :90.5%). The pooled data from trials of vitamin D supplementation with dosage of ≤4000 IU/day (- 0.37, 95% CI: -0.65, - 0.10, I2 : 73.5%) significantly reduced vWF concentrations, while there was no effect of vitamin D supplementation on vWF concentrations among trials with the dosage of intervention > 4000 IU/day (- 0.17, 95% CI: -0.43, 0.10, I2 : 0.0%). VWF concentrations significantly reduced in pooled data from trials with duration study ≤8 weeks (- 0.37, 95% CI: -0.67, - 0.07, I2 : 60.6%), but there was no effect of vitamin D supplementation on vWF concentrations among trials with > 8 weeks (- 0.20, 95% CI: -0.45, 0.05, I2 : 0.0%). While there was no effect of vitamin D supplementation on vWF concentrations among trials with total sample size of ≤60 patients (- 0.03, 95% CI: -0.42, 0.36, I2 : 0.0%), vWF concentrations in trials with more than 60 patients decreased significantly (- 0.34, 95% CI: -0.56, - 0.12, I2 : 60.9%).
Conclusions: Overall, the current meta-analysis demonstrated that vitamin D supplementation to patients with metabolic syndrome and related disorders resulted in an improvement in vWF, but did not affect ICAM-1, VCAM-1, E-selectin and endothelin levels.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app